What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall involving a specific batch of compounded sterile injectable medication distributed by Apollo Care, LLC. This action was taken to address safety concerns regarding the integrity of the product being administered to patients across the nation. The company responsible for this distribution is located at 3801 Mojave Ct, Ste 102, Columbia, MO 65202. While the facility is based in Missouri, it is important to understand that the scope of this recall is not limited to a single region or clinic; the affected products were distributed nationwide within the United States, meaning patients in any state could potentially be impacted.
The specific product at the center of this recall is Semaglutide 5mg (1mg/mL) combined with Glycine 25 mg (5mg/mL). This formulation is packaged in 5 mL Sterile Multi-Dose Vials. It is crucial to note that these are prescription-only drugs intended strictly for subcutaneous injection, meaning they are designed to be injected into the fatty tissue under the skin, not taken orally or administered intravenously. The brand associated with this recall is Apollo Care. Because this is a compounded medication, it may not carry the standard branding of major pharmaceutical manufacturers, but the National Drug Code (NDC) serves as the unique identifier for tracking purposes. The specific NDC for the recalled items is 71170-712-03.
To determine if you have been affected by this recall, you must look closely at the lot number and expiration date on your vial. The only lot number identified in this recall action is AC-017272. This specific lot has an expiration date of December 12, 2026 (Exp. 12/12/2026). If you have a vial with a different lot number or expiration date, it is not part of this specific recall action, although you should always verify the authenticity and source of any compounded medication with your healthcare provider. The recall was officially initiated on July 29, 2026. At this time, the FDA has not stated a specific remedy or replacement plan for consumers, nor have they provided details on the exact number of units involved in this distribution. However, the classification as a Class II recall indicates that use of this product could cause temporary health problems or pose a slight threat of a serious nature, depending on the severity of the reaction to the contamination.
The distribution pattern for these vials was nationwide, which underscores the importance of checking your records immediately. Whether you received this medication directly from Apollo Care’s facility in Columbia, MO, or through an intermediary pharmacy or clinic in another state, the product specifications remain the same. The combination of Semaglutide and Glycine in a multi-dose vial format requires careful handling to maintain sterility, which is precisely why the presence of foreign particulate matter is such a significant concern in this instance.
The hazard, explained
When the FDA issued this recall for Apollo Care, LLC’s Semaglutide product, the core issue identified was the presence of particulate matter within the sterile multi-dose vials. In plain terms, this means that tiny, unintended solid particles were found inside what should have been a clean liquid solution. The investigation determined these foreign objects to be of two specific types: nylon or polyamide material, and silk or proteinaceous material. To understand why this is a serious safety concern, it helps to look at how these substances interact with the human body when introduced via injection.
Semaglutide is designed for subcutaneous injection, meaning it is meant to be delivered into the fatty tissue just beneath the skin. This route of administration relies on the drug being in a highly controlled, sterile state. When particulate matter such as nylon fibers or silk proteins enters the vial, it typically indicates a failure in the manufacturing process or packaging integrity. Nylon, a synthetic polymer often used in medical device components like filters or syringe barrels, can shed microscopic fragments if there is friction or wear during filling. Silk or proteinaceous debris often suggests contamination from biological sources or improper cleaning of equipment that previously handled such materials.
The danger arises not just from the presence of these particles, but from how the body reacts to them once injected. Unlike fluids that dissolve and circulate naturally, solid particulates can become lodged in capillaries or tissues. If these particles are non-biodegradable, like nylon, they remain in the body indefinitely, potentially causing chronic inflammation or granuloma formation—small areas of irritated tissue that form when the immune system attempts to wall off foreign material. Proteinaceous materials, such as silk, can trigger allergic reactions or immune responses in sensitive individuals, leading to redness, swelling, or more severe systemic reactions.
Furthermore, because these are multi-dose vials, the contamination could affect every subsequent dose drawn from that single container. A patient might unknowingly inject multiple doses containing these foreign bodies over time, compounding the risk. While the immediate physical trauma of a tiny particle is often minimal, the cumulative effect and the potential for infection if the particles carry bacteria cannot be overlooked. This is why the FDA classifies such defects seriously; they compromise the sterility and purity that are fundamental to safe injectable drug therapy.
It is also important to note that Semaglutide itself is a potent medication used for blood sugar control and weight management. Any alteration to its sterile environment introduces variables that the body must fight against, diverting resources from the drug’s intended therapeutic effect. The presence of foreign matter essentially turns a precise medical tool into an unpredictable variable, where the harm comes not from the drug working too well, but from the body reacting to the contaminants mixed within it.
Who is most at risk
To understand who is most at risk from this specific FDA recall involving Apollo Care, LLC’s Semaglutide product, we first need to look at the nature of the medication itself. Semaglutide is a prescription drug primarily used to treat type 2 diabetes and, in some cases, for weight management under strict medical supervision. It works by mimicking a hormone that targets areas of the brain involved in regulating appetite and food intake. Because it is an injectable medication administered subcutaneously (under the skin), the people most directly at risk are those who have been prescribed this specific formulation to manage their metabolic health.
The primary group affected by this recall consists of patients currently using Lot AC-017272, which expires on December 12, 2026. These individuals rely on the medication to maintain stable blood sugar levels or adhere to a weight management plan. The risk here is not just about missing a dose; it is about introducing foreign contaminants into their bodies. The recall cites the presence of particulate matter identified as nylon/polyamide and silk/proteinaceous-type material within the sterile multi-dose vials. For any user, but particularly for those with compromised immune systems or chronic conditions like diabetes, injecting these microscopic particles can lead to serious complications. These particles do not dissolve in the body; instead, they can cause inflammation at the injection site, trigger localized allergic reactions, or potentially enter the bloodstream and travel to other organs, causing blockages or immune responses.
While any patient using this lot is technically at risk, certain subgroups face heightened vulnerability due to their physiological state. Individuals with diabetes often have weakened circulatory systems and reduced sensitivity in their extremities, making them more susceptible to infections or poor wound healing at injection sites. If particulate matter causes tissue damage or introduces a pathogen carrier, the body’s ability to repair itself may be impaired. Furthermore, patients who are elderly or those with pre-existing cardiovascular issues are at greater risk because foreign particles entering the bloodstream can pose a threat to heart health or cause embolic events, where particles block small blood vessels.
Additionally, because this is a multi-dose vial, the risk is compounded by the potential for repeated exposure. Unlike single-use syringes, multi-dose vials are designed to be accessed multiple times over a period. If the particulate contamination is present throughout the vial, each subsequent injection increases the cumulative load of foreign material in the body. This is particularly concerning for patients who inject daily or weekly as part of their routine care. The proteinaceous nature of some of the debris also raises the risk of sensitization, meaning that repeated exposure could lead to developing an allergic response over time, even if no immediate reaction occurs after the first few doses.
In summary, the individuals most at risk are those who possess and use Semaglutide 5mg (1mg/mL) from Lot AC-017272. Within this group, those with diabetes, cardiovascular conditions, or weakened immune systems face the most severe potential health consequences due to the systemic nature of injectable particulate contamination.
How to tell if you have the recalled item
If you believe you might have purchased or been prescribed the specific batch of Semaglutide affected by this FDA recall, careful inspection of your medication packaging is essential. Because this is a prescription drug produced by Apollo Care, LLC, the identification process relies on verifying several distinct details printed directly on the vial and its outer carton. You will need to look for exact matches across four key areas: the product name and strength, the National Drug Code (NDC), the lot number, and the expiration date. Missing even one of these identifiers means your specific vial is likely not part of this recall, so take your time to check each point.
First, examine the label on the sterile multi-dose vial itself, as well as the box it came in. The product must be identified as SEMAGLUTIDE 5mg (1mg/mL) combined with Glycine 25 mg (5mg/mL). It should be clearly marked as a 5 mL Sterile Multi-Dose Vial intended for Rx Only use and specifically labeled "For Subcutaneous Injection Only." The manufacturer is Apollo Care, located at 3801 Mojave Ct, Ste 102, Columbia, MO 65202. If the label lists a different manufacturer, different concentration, or a different form of administration (such as oral tablets), this recall does not apply to you.
The most critical step is checking the unique identifiers printed on the packaging. You must locate the National Drug Code, which serves as the product’s specific fingerprint in this case. The recalled items carry the NDC 71170-712-03. Next, look for the Lot Number. This recall affects only vials with the Lot Number AC-017272. Finally, check the expiration date printed on the label. The affected vials are scheduled to expire on 12/12/2026. If your lot number is different, or if the expiration date does not match exactly, you do not have a recalled unit.
While this recall is distributed nationwide within the United States, the manufacturer’s address confirms the source as Columbia, Missouri. However, distribution location alone cannot confirm whether your vial is affected; only the NDC, lot number, and expiration date can provide that certainty. If you are unsure or if the labels are worn or illegible, do not attempt to guess. Contact your pharmacy or healthcare provider immediately with the information you have. They can help verify the batch details against FDA recall databases. Do not use any medication if you cannot positively confirm all four identifiers match the recalled items described above.
What to do — step by step
If you have received or purchased the recalled Apollo Care Semaglutide product, your immediate priority is to ensure your safety and prevent any potential harm from using a compromised medication. The FDA has identified this specific recall as Class II, which indicates that use of the product may cause temporary health problems or pose a slight threat of a serious nature. Because the remedy for this specific recall has not been explicitly stated by the manufacturer or the agency in the available records, you cannot rely on a standard return-for-replacement process at this moment. Instead, you must take proactive steps to secure your health and verify the status of your medication.
First, stop using the product immediately. Do not administer any injections from the vial, regardless of how much liquid remains or when it was opened. The hazard involves the presence of particulate matter—specifically identified as nylon/polyamide and silk/proteinaceous-type material—which could introduce foreign substances directly into your body through subcutaneous injection. Even if the vial appears clear to the naked eye, microscopic particles may be present. Continuing to use this medication poses an unnecessary risk of infection, inflammation, or other adverse reactions that are not part of the intended therapeutic effect of Semaglutide.
Next, carefully check your inventory against the specific details provided in the recall notice. You need to verify that you possess the exact item listed in the FDA report. Look for the National Drug Code (NDC) 71170-712-03 on the packaging. Confirm that the lot number is AC-017272 and that the expiration date is listed as December 12, 2026. These identifiers are critical because recalls often affect only specific batches manufactured during a particular window. If your vial does not match these exact details, it is likely not part of this specific recall, but you should still consult your healthcare provider to be certain.
Since the official remedy is not stated, you must take the initiative to contact the responsible parties. Reach out to Apollo Care, LLC, located at 3801 Mojave Ct, Ste 102, Columbia, MO 65202. They are the entity responsible for this distribution and may have additional instructions that were not included in the initial public summary. Additionally, inform your healthcare provider or pharmacist who prescribed or dispensed the medication. They can help you manage any gaps in your treatment plan and may have received direct communication from the manufacturer regarding alternative options or refunds. Do not attempt to dispose of the medication in your household trash without proper guidance, as pharmaceutical waste requires specific handling procedures to protect public health and the environment.
Finally, monitor yourself for any unusual symptoms if you have already used some of this product. While the recall is based on contamination risks rather than confirmed adverse events, being vigilant is a prudent safety measure. Document any side effects or concerns and report them to your doctor. Keep the vial and its packaging in a safe place until you have spoken with Apollo Care or your healthcare provider, as they may request the physical item for inspection or proof of possession. Stay calm, but act promptly to ensure your medical needs are met safely and correctly.
Your refund, repair, or replacement options
When a pharmaceutical product is recalled, the most immediate concern for patients and healthcare providers is often: "What happens next?" In this specific case involving Apollo Care, LLC’s recall of Semaglutide 5mg (1mg/mL) combined with Glycine 25 mg (5mg/mL), the official FDA recall filing does not explicitly state a standardized remedy such as a direct refund, a prepaid return shipping label, or an automatic replacement program. This absence of a detailed consumer-facing remediation plan in the public record is actually quite common for Class II recalls involving compounded or specialized sterile injectables. It does not mean you are left without recourse; rather, it means the process is likely managed directly between the distributor and the entities that purchased or received the product.
Because this is a prescription drug intended for subcutaneous injection and classified as "Rx Only," the remedy is typically handled through professional channels rather than a consumer retail return process. The primary point of contact for any resolution—whether it involves returning the unused vials, discussing credit for the product, or obtaining a safe replacement from a different lot—is Apollo Care, LLC itself. You can reach them at their listed address: 3801 Mojave Ct, Ste 102, Columbia, MO 65202. It is crucial to contact them directly using the information provided in the official recall notice or through your pharmacy’s procurement department if you purchased it through a medical supplier.
If you are a patient who has already received this medication, do not attempt to use it under any circumstances due to the identified hazard of particulate matter. Instead, return the vial immediately to the pharmacy or healthcare provider from whom you obtained it. They will have the specific instructions for disposing of the product safely and may coordinate with Apollo Care to determine if a replacement is available from a non-recalled lot. If you are a retailer or clinic holding inventory, you should segregate the affected units (NDC 71170-712-03, Lot AC-017272) immediately and contact Apollo Care to arrange for their return or destruction. The remedy will likely involve a credit memo or replacement stock once the hazard is verified, but these terms are not publicly detailed in the initial FDA announcement.
Until you receive specific instructions from Apollo Care or your healthcare provider, assume that no automatic refund has been processed. Keep all documentation, including your prescription record, the lot number (AC-017272), and the expiration date (12/12/2026) on hand to facilitate a smoother resolution when you make contact. Your safety is the priority here, so follow the disposal instructions provided by your medical professional strictly, and let the manufacturer handle the logistical details of the recall remedy.
What can happen if you ignore it
When a medication is recalled due to the presence of particulate matter, the primary concern shifts from whether the drug will work to whether it might cause direct physical harm. In this specific case involving Apollo Care’s Semaglutide vials, investigators identified foreign materials described as nylon/polyamide and silk/proteinaceous-type substances. Ignoring a recall for a product with these kinds of contaminants is not merely a matter of inconvenience; it introduces unnecessary and significant risks to your health that could be entirely avoided.
The most immediate danger lies in the nature of the injection itself. Semaglutide is administered via subcutaneous injection, meaning the medication is delivered directly into the fatty tissue just beneath the skin. When you draw this solution from a multi-dose vial, any particulate matter suspended within the liquid can be drawn into the needle. While these particles may seem microscopic and harmless to the eye, they are foreign objects entering your body’s internal systems. If injected, these particles can cause localized trauma at the injection site. This often presents as severe pain, swelling, redness, or the formation of sterile abscesses—collections of pus or inflammatory cells that form in response to the foreign material rather than an infection.
Beyond the injection site, there is a risk of systemic complications. Although rare with subcutaneous administration compared to intravenous use, particles can potentially enter the bloodstream depending on how deep the needle is placed or if minor blood vessels are nicked. Once in circulation, foreign bodies like nylon fragments or proteinaceous debris can trigger an immune response. For many people, this might result in a localized inflammatory reaction that resolves on its own, but for others, it can lead to granuloma formation (small areas of inflammation) or embolic events where particles block small blood vessels. This is particularly concerning if the particulate matter includes materials that do not dissolve or break down easily in the body.
Furthermore, ignoring the recall means missing out on a remedy that protects you from uncertainty. While the specific remedy for this recall was not stated in the official FDA notice, continuing to use the product keeps you exposed to unpredictable variables. You cannot filter out these particles at home with standard household tools, and shaking or stirring the vial does not remove solid contaminants—it may only redistribute them. By using the recalled lot AC-017272, you are essentially gambling with your tissue integrity and immune system for no benefit, since a safe, verified alternative is available through the recall process.
Finally, there is the risk of delaying proper medical care. If you experience adverse reactions such as unexplained lumps, severe pain, or signs of infection at the injection site after using contaminated medication, it can be difficult for healthcare providers to determine the cause without knowing about the recall. This diagnostic confusion can lead to misdiagnosis or delayed treatment. Staying informed and acting on the recall ensures that any health issues are addressed in the context of known risks, allowing your doctor to provide the most accurate and effective care possible.
Staying safe: broader tips
When dealing with compounded pharmaceuticals or sterile injectables outside of a traditional hospital setting, vigilance is your most effective tool for prevention. While regulatory agencies like the FDA work tirelessly to monitor the supply chain, the final check often happens in your own home. One of the most critical steps you can take is to always inspect any medication upon receipt and before administration. Look closely at the liquid for clarity. If you see even tiny specks, cloudiness, or unusual discoloration that wasn’t present when the vial was sealed, do not use it. These visual cues are often the first sign of particulate contamination, which can occur during manufacturing, packaging, or handling. It is better to contact your provider for a new batch than to risk introducing foreign material into your body.
Proper storage and handling play an equally vital role in maintaining the integrity of multi-dose vials. Many people assume that as long as a medication is within its expiration date, it is safe to use. However, once a sterile vial is pierced, the risk of contamination increases with every access. Ensure you are using clean needles and syringes each time, and follow any specific storage instructions provided by your pharmacist or manufacturer regarding temperature and light exposure. Storing medications in their original packaging until you are ready to use them can also help protect them from environmental contaminants. Always wash your hands thoroughly before handling any medical supplies, and keep your injection site clean to prevent introducing bacteria at the point of entry.
Beyond physical inspection, stay informed about the broader landscape of drug safety. Subscribe to email alerts from the FDA’s official website or use their mobile app to receive real-time notifications about recalls affecting specific drugs or manufacturers. This proactive approach ensures you are not caught off guard by issues that may arise after your prescription was filled. Additionally, maintain an open line of communication with your healthcare provider and pharmacist. If you notice any unusual symptoms or have concerns about the quality of a product, report them immediately. Your feedback contributes to a larger network of safety monitoring that helps protect the entire community. By combining careful personal inspection with reliable information sources, you take control of your health safety in a practical, empowering way.
- Always visually inspect liquids for particles or cloudiness before use.
- Store medications according to manufacturer guidelines to preserve sterility.
- Register for FDA recall alerts to stay informed about new safety issues.